Zymeworks 64.5% ORR in Phase 1 platinum-resistant ovarian cancer study at ESMO 2026
Zymeworks reports 64.5% ORR for FRĪ±-targeting ADC ZW191 in Phase 1 platinum-resistant ovarian cancer study at ESMO 2026
- Phase 1 data presented at ESMO 2026 involved heavily pretreated, platinum-resistant ovarian cancer patients.
- ZW191 achieved a 64.5% confirmed objective response rate at the 6.4 mg/kg dose with favorable safety profile.
- Results support continued clinical development of ZW191 and potential partnering.
- Roche and Zymeworks signed an exclusive global license and collaboration for DLL3-targeting trispecific T cell engager ZW209.
- Roche to pay $55M upfront, $40 million Phase 1b milestone and up to $718 million in additional milestones.
- Zymeworks is also eligible for tiered royalties on potential future sales of ZW209.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.